Christophe Weber: The Man Reshaping Takeda

Christophe Weber became president and CEO of Japan's Takeda Pharmaceutical on April 1, 2015, in the process becoming both the first non-Japanese and first corporate outsider to hold the position at the more than 230-year old company. He has since initiated a ground-up refocusing and restructuring that will alter the fundamental shape of the company while retaining its core identity.

This article forms part of Scrip 100 2016's Leadership chapter, in which the pharmaceutical industry's c-suite talk exclusively to Scrip. Other articles included in this chapter are:

More from Business

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By 

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By 

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

More from Scrip

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.